Abstract: Provided are a method for maintaining Walker constellation formation and a terminal device. The method comprises: determining a first offset amount of each satellite within a simulation time period according to parameters of a Walker constellation; performing first offset on each satellite according to the first offset amount to obtain a Walker constellation after the first offset; determining a second offset amount of each satellite within the simulation time period according to parameters of the Walker constellation after the first offset; and superimposing the first offset amount and the second offset amount, and performing second offset on each satellite so as to maintain the formation of the Walker constellation.

Abstract: Provided is a fused ring diimide derivative having a chemical structure of formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-proliferative activity on various cancer cells is significantly better than that of similar compounds.

Abstract: The disclosure describes a low-orbit satellite deorbit control method and system based on a particle swarm algorithm. The method includes: constructing an objective function according to a position parameter and a perturbation acceleration of each of particles in a particle swarm as well as a preset Lagrangian multiplier and a penalty factor; determining an objective fitness of each particle and a population fitness of the particle swarm based on the objective function, updating the position parameter and the velocity of each particle, and obtaining a population optimal fitness at a maximum number of iterations; updating the Lagrangian multiplier and the penalty factor according to the population optimal fitness, comparing the objective deviation value with a preset convergence condition, and determining an objective population fitness and an objective position parameter according to a comparison result to obtain an objective deorbit mode.

Abstract: A system for a data-parallel execution of at least two implementations of an application on reconfigurable processors with different layouts is presented. The system comprises a pool of reconfigurable data flow resources with data transfer resources that interconnect first and second reconfigurable processors having first and second layouts that impose respective first and second constraints for the data-parallel execution of the application. The system further comprises an archive of configuration files and a host system that is operatively coupled to the first and second reconfigurable processors. The host system comprises first and second compilers that generate for the application, based on the respective first and second constraints, first and second configuration files that are stored in the archive of configuration files and adapted to be executed data-parallel compatible on respective first and second reconfigurable processors.

Abstract: A system for executing an application on a pool of reconfigurable processors with first and second reconfigurable processors having first and second architectures that are different from each other is presented. The system comprises an archive of configuration files with first and second configuration files for executing the application on the first and second reconfigurable processors, respectively, and a host system that is operatively coupled to the first and second reconfigurable processors. The host system comprises a runtime processor that allocates reconfigurable processors for executing the application and an auto-discovery module that is configured to perform discovery of whether the reconfigurable processors include at least one of the first reconfigurable processors and whether the reconfigurable processors include at least one of the second reconfigurable processors.

Abstract: A drug, food and application of an anti-coronavirus infection, the drug or food containing lysozyme or a combination that comprises lysozyme; the lysozyme or a combination thereof can be used to prepare a drug for anti coronavirus infection and preventing or treating coronavirus-related diseases or symptoms, or food for assisting in anti coronavirus infection and assisting in preventing or treating coronavirus-related diseases or symptoms. The present disclosure has a good preventive and therapeutic effect on coronavirus infection or related diseases or symptoms thereof; in addition, the present application can accelerate the elimination of the virus in vivo, accelerate the speed of coronavirus nucleic acid tests in vivo turning negative, shorten the course of a patient's illness, effectively prevent and reduce the spread of coronavirus, and also has important social benefits and good application prospects.

Abstract: The present disclosure provides a piperacillin-containing composition, which further containing a certain proportion of ampicillin and sulbactam. The present disclosure further provides a pharmaceutical formulation thereof and the use thereof. The composition and pharmaceutical formulation of the present disclosure can inhibit the drug-resistant Acinetobacter baumannii, and particularly have therapeutic effects on the infection caused by Acinetobacter baumannii which is resistant to carbapenem or cefoperazone-sulbactam.

Abstract: Disclosed is a drug combination for preventing or treating irritable bowel syndrome. The drug combination comprises dosmalfate and lysozyme.

Abstract: The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.

Abstract: Disclosed in the present invention is use of lysozyme in the preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, and a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid and promoting uric acid excretion.

Abstract: Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in the preventing psoriasis, treating of psoriasis, and/or preventing of psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc.

Abstract: A compound for regulating body weight imbalance, a composition thereof and an application thereof. The inventor unexpectedly discovered that diosmin hydrogen sulfate derivatives have the effects of regulating body weight imbalance, and are expected to be developed as safe and effective weight imbalance regulators or used as synergists to improve the regulatory effects of existing weight imbalance regulators.

Abstract: The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.

Abstract: A display panel and a display device. The display panel includes: a substrate layer, a flexible screen body, an adhesive layer and a touch control layer that are stacked in order. Each of the substrate layer, the flexible screen body, the adhesive layer and the touch control layer has a particular film/layer thickness. At least part of the adhesive layer is configured as a neutral layer of the display panel. Both the substrate layer and the flexible screen body are subject to a compressive stress when the display panel is bent. The touch control layer is subject to a tensile stress when the display panel is bent.

Abstract: Provided are a method for maintaining Walker constellation formation and a terminal device. The method comprises: determining a first offset amount of each satellite within a simulation time period according to parameters of a Walker constellation; performing first offset on each satellite according to the first offset amount to obtain a Walker constellation after the first offset; determining a second offset amount of each satellite within the simulation time period according to parameters of the Walker constellation after the first offset; and superimposing the first offset amount and the second offset amount, and performing second offset on each satellite so as to maintain the formation of the Walker constellation.

Abstract: An image processing method is provided. The method includes: encoding an input image based on an attention mechanism to obtain an encoding tensor set and an attention map set of the input image; obtaining an encoding result of the input image according to the encoding tensor set and the attention map set, the encoding result of the input image recording an identity feature of a human face in the input image; encoding an expression image to obtain an encoding result of the expression image, the encoding result of the expression image recording an expression feature of a human face in the expression image; and generating an output image according to the encoding result of the input image and the encoding result of the expression image, the output image having the identity feature of the input image and the expression feature of the expression image.

Abstract: The disclosure describes a low-orbit satellite deorbit control method and system based on a particle swarm algorithm. The method includes: constructing an objective function according to a position parameter and a perturbation acceleration of each of particles in a particle swarm as well as a preset Lagrangian multiplier and a penalty factor; determining an objective fitness of each particle and a population fitness of the particle swarm based on the objective function, updating the position parameter and the velocity of each particle, and obtaining a population optimal fitness at a maximum number of iterations; updating the Lagrangian multiplier and the penalty factor according to the population optimal fitness, comparing the objective deviation value with a preset convergence condition, and determining an objective population fitness and an objective position parameter according to a comparison result to obtain an objective deorbit mode.

Abstract: The present disclosure provides a piperacillin-containing composition, which further containing a certain proportion of ampicillin and sulbactam. The present disclosure further provides a pharmaceutical formulation thereof and the use thereof. The composition and pharmaceutical formulation of the present disclosure can inhibit the drug-resistant Acinetobacter baumannii, and particularly have therapeutic effects on the infection caused by Acinetobacter baumannii which is resistant to carbapenem or cefoperazone-sulbactam.

Abstract: A method for obtaining a sequoyitol-containing extract from a plant of genus Nephrolepis, comprising extracting with a solvent, recovering the solvent to give an extractum, subjecting the extractum to two-phase extraction and column chromatography, collecting the fractions containing sequoyitol, concentrating, filtration and drying. The main active ingredient of the extract obtained is sequoyitol, which can be used for treating diabetes and its complications.

Abstract: The method for obtaining a sequoyitol-containing extract from a plant of the genus of Trifolium, Leguminosae or Ginkgoaceae, an extract obtained by the method and the use of the extract for the preparation of medicaments for treating diabetes and its complications, the method comprises the steps of extracting with a solvent, recovering the solvents to give an extractum, subjecting the extractum to two-phase extraction and column chromatography, collecting the fractions containing sequoyitol, concentrating, filtration and drying.